The current small-cap cycle is being shaped by one of the most pronounced valuation dislocations between large-cap and small-cap equities in a generation. According to CME Group research, small-cap stocks have not been this cheap relative to large-caps on a price-to-sales or price-to-book basis since 1999, the beginning of what proved to be a multi-year period of small-cap outperformance. Entering 2026, the forward price-to-earnings discount of the Russell 2000 relative to the S&P 500 had widened to approximately 31%, with the Russell 2000's trailing P/E compressing to 19.5x against the S&P 500's premium valuation of nearly 30x.
The Federal Reserve delivered three consecutive 25-basis-point rate cuts in late 2025, bringing the federal funds rate to a target range of 3.50% to 3.75%. Because approximately 32% of Russell 2000 debt is tied to floating rates, compared to roughly 6% for the S&P 500, the easing cycle has a disproportionately direct effect on the cost structures of smaller companies. As of late March 2026, the iShares Russell 2000 ETF had declined approximately 10.9% from its January peak as stronger-than-expected inflation readings reduced near-term rate cut expectations. That pullback has widened the valuation gap further — a condition that, based on CME Group's documented cycle history, has typically preceded the most meaningful periods of small-cap mean reversion.
Against that backdrop, several companies featured on the RedChip stock portal illustrate the divergent trends currently shaping the small-cap landscape.
Strategic Minerals Gain Attention
On November 7, 2025, the U.S. Geological Survey published its final 2025 List of Critical Minerals in the Federal Register, designating 60 minerals as essential to U.S. economic and national security, an expansion from 50 minerals on the prior 2022 list. Antimony, niobium, scandium, and titanium all appear on that list. The Silverado Policy Accelerator has identified antimony as one of only 12 "strategic defense critical minerals," essential to missile systems, military aircraft, and ammunition, with the U.S. dangerously dependent on foreign entities of concern for supply. Federal designation triggers procurement preferences, domestic investment incentives, and allied-nation sourcing agreements, a policy dynamic that has begun to move capital toward companies controlling permitted domestic deposits.
NioCorp Developments Ltd. controls the Elk Creek project in Nebraska, one of the few large-scale domestic deposits containing niobium, scandium, and titanium, all three designated on the USGS 2025 list. As North American and European governments pursue supply-chain resilience for materials used in aerospace, defense, and advanced electronics, permitted deposits of this scale have become increasingly difficult to replicate.
Nova Minerals Ltd. controls a substantial gold resource in Alaska and is evaluating the antimony potential of its holdings. The convergence of elevated gold prices, which averaged $4,135 per ounce in Q4 2025 according to the World Gold Council, and renewed institutional focus on antimony has placed companies with dual-commodity exposure in an unusual position relative to single-commodity peers.
AI Infrastructure Expands Beyond Mega-Caps
Gartner projects total worldwide AI spending will reach $2.52 trillion in 2026, a 44% increase year-over-year, with AI infrastructure accounting for approximately $1.37 trillion of that total. Separately, IDC data shows organizations increased spending on compute and storage infrastructure for AI deployments by 166% year-over-year in Q2 2025, reaching $82.0 billion in a single quarter, with the global AI infrastructure market on track to reach $758 billion in annual spending by 2029. That level of capital deployment by hyperscalers creates layered demand through the supply chain, demand that does not accrue exclusively to the largest semiconductor manufacturers.
Sharon AI Inc. represents one emerging participant in that ecosystem. Per SEC filings associated with its pending business combination with Roth CH Acquisition Co. (OTC: USCTF), Sharon AI is a certified NVIDIA Cloud Partner offering GPU Compute-as-a-Service inside Tier IV co-location data centers via a proprietary orchestration and automation platform. Its GPU fleet includes NVIDIA H200, H100, and L40S hardware alongside AMD MI300X accelerators. The company is also co-developing, through a 50/50 joint venture, a planned 1GW-plus AI and high-performance computing campus in West Texas. The business combination with Roth CH, which would take the combined entity public in U.S. markets, remains pending as of this writing.
Biotechnology Catalysts Drive Volatility
Connect Biopharma Holdings Ltd. (Nasdaq: CNTB) is developing rademikibart, a fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Ra) — the shared receptor subunit for the IL-4 and IL-13 cytokines driving Type 2 inflammatory disease. The mechanism positions rademikibart for both maintenance and acute-exacerbation settings in asthma and COPD, differentiating it from existing biologics focused primarily on maintenance therapy. Per the company's April 2025 announcement of a positive Type C meeting with the FDA's Division of Pulmonology, Allergy, and Critical Care, the agency acknowledged the unmet need in the 28-day post-exacerbation window — a period in which approximately 45% of patients on the current standard of care experience treatment failure. Topline data from both the Phase 2 Seabreeze STAT asthma and COPD studies is expected in the first half of 2026. Supporting data presented at the European Respiratory Society Congress in September 2025 showed a 507 milliliter improvement in prebronchodilator FEV1 at Week 24 in the high eosinophil subgroup, along with a 63% reduction in exacerbations. The company reported cash and short-term investments of $54.8 million as of September 30, 2025, with a stated runway into 2027.
AbCellera Biologics Inc. (Nasdaq: ABCL) operates as an antibody discovery engine, integrating machine learning, proprietary hardware, and biological screening platforms to accelerate therapeutic antibody identification for pharmaceutical partners. Per full-year 2024 SEC filings, AbCellera had accumulated 96 partner-initiated program starts with downstream economics, with partners advancing 16 molecules into the clinic. Named partners include Eli Lilly, with whom AbCellera expanded a collaboration in July 2024 to cover immunology, cardiovascular disease, and neuroscience; AbbVie, with whom AbCellera expanded a T-cell engager collaboration in oncology in 2025; and Biogen, with whom a neurological conditions collaboration was announced in Q1 2024. The platform model distributes risk across a portfolio of partner programs, insulating the company from single-asset binary outcomes while maintaining upside participation through royalties and milestones.
Technology and Automation Themes
8x8 Inc. (Nasdaq: EGHT) operates a cloud-based unified communications platform serving enterprises transitioning from legacy telephony infrastructure. The broader enterprise SaaS sector experienced significant valuation compression as higher interest rates reduced investor appetite for growth-oriented technology companies. The stabilization of borrowing costs creates a more constructive backdrop for companies in this category improving their unit economics, though near-term performance remains sensitive to rate expectations.
A2Z Cus2Mate Solutions Corp. (NASDAQ: AZ) develops automated shopping cart systems and retail analytics platforms designed to reduce in-store labor costs for grocery and general merchandise retailers, a segment defined by sustained structural labor cost pressure unlikely to abate as minimum wage legislation advances across major U.S. states.
Consumer and Precious-Metals Exposure
a.k.a. Brands Holding Corp. (NYSE: AKA) operates a portfolio of digitally native fashion brands targeting younger consumers across direct-to-consumer e-commerce channels, a segment that has experienced earnings volatility as discretionary spending fluctuates with inflation and consumer confidence.
A-Mark Precious Metals Inc. (Nasdaq: AMRK) is a full-service precious metals trading company involved in wholesale distribution, minting, and financing of gold, silver, platinum, and palladium products. According to the World Gold Council's full-year 2025 Gold Demand Trends report, total gold demand exceeded 5,000 tonnes for the first time in history, generating a record $555 billion in total market value, a 45% increase year-over-year, with bar and coin demand reaching a 12-year high of 1,374.1 tonnes. J.P. Morgan Global Research projects bar and coin demand to again surpass 1,200 tonnes in 2026. A-Mark's revenue profile is correlated with physical demand volume, not solely with price, a distinction that matters when simultaneous inflows across ETFs, bars, coins, and central bank purchases confirm structural rather than speculative demand support.
Analytical Technology
908 Devices Inc. (Nasdaq: MASS) manufactures portable mass spectrometry and infrared spectroscopy instruments for rapid chemical identification across law enforcement, defense, hazmat response, and customs enforcement. In 2025, the Texas Department of Public Safety placed a $2 million order for MX908 devices through the federal COPS grant program, and the U.S. Coast Guard expanded its MX908 fleet to more than 35 devices.
Per the company's Q4 2025 earnings call, 27% of 2025 revenues came from outside the U.S., with accelerating adoption across NATO member states driven by increased European defense budgets. Management projected 15% to 20% top-line growth in 2026, citing modernization demand driven by geopolitical tensions and evolving chemical threat vectors. A pending Department of Defense program, the AVCAD initiative in partnership with Smiths Detection, is nearing its next phase, with an initial production run of several hundred systems under evaluation. If advanced, AVCAD would represent a transition from project-based revenue to a program-of-record model, a structural shift in revenue durability not yet reflected in the current valuation.
Market Outlook
The defining characteristic of the current small-cap market is selectivity, not structural weakness. The Russell 2000's pullback from January highs reflects sensitivity to interest rate expectations, not a reassessment of the underlying asset class case. The companies reviewed here share exposure to demand drivers, critical minerals policy, AI infrastructure buildout, clinical catalysts, defense modernization, and physical precious metals demand, that are independent of short-term economic sentiment. The near-term catalyst density is highest in biotechnology, where Connect Biopharma's H1 2026 Phase 2 readouts represent a defined, time-bound event. Across other sectors, the catalysts are more diffuse but no less structural.
In a market that continues to reward concentration and punish indiscriminate risk-taking, the investor framework remains consistent: verify the structural thesis against primary data, identify companies with specific near-term catalysts, and assess balance sheet durability.
This commentary is provided for informational purposes only and does not constitute investment advice. All figures and attributions are sourced from primary sources including company SEC filings, U.S. government publications, and named institutional research as cited. Past performance of market cycles does not guarantee future results